CV outcomes for adult patients with type 2 diabetes and established cardiovascular disease LEADERa landmark CVOT for Victoza 1 9,340 patients Key inclusion criteria: T2D, A1C 7.0% Age 50 years and established CVD OR Age 60 years and risk factors for CVD Cardiovascular standards of care (antihypertensives, lipid-lowering agents, and antiplatelet therapy) Diabetes standards of care (lifestyle modification, OADs, and insulin) Duration 3.5-5 years Time to first major adverse cardiovascular event (MACE) composed of: Composite primary endpoint CV death Nonfatal MI Nonfatal stroke Prospectively designed and powered to assess noninferiority and then superiority Patients were titrated to maximum tolerated dose of 0.6 mg to 1.8 mg Median daily dose of Victoza was 1.78 mg Victoza significantly reduced MACE in adults with T2D and established CVD 1 Absolute risk reduction: 1.9% Median time of exposure to treatment: 3.5 years
Clean Provider Records Perfect I looked up The Pharmacy Hub, the one pharmacy name provided to me, and found no disciplinary actions on file
3 , 285292, doi: 10.1513/pats.200601-005TK (2006)
Like vitamin injections, vitamin infusions Gig Harbor bypass the digestive system, delivering nutrients directly to the bloodstream for faster, more effective results
This supports your body's natural detoxification processes following infusion
Furthermore, it was reported that this risk increases with the duration of exposure to GLP-1 receptor agonists, with the highest risk observed after 1.6 years
